PL3250563T3 - Podstawione triazole i dotyczące ich sposoby - Google Patents

Podstawione triazole i dotyczące ich sposoby

Info

Publication number
PL3250563T3
PL3250563T3 PL16703250T PL16703250T PL3250563T3 PL 3250563 T3 PL3250563 T3 PL 3250563T3 PL 16703250 T PL16703250 T PL 16703250T PL 16703250 T PL16703250 T PL 16703250T PL 3250563 T3 PL3250563 T3 PL 3250563T3
Authority
PL
Poland
Prior art keywords
methods relating
substituted triazoles
triazoles
substituted
relating
Prior art date
Application number
PL16703250T
Other languages
English (en)
Polish (pl)
Inventor
John P. Williams
Deborah Slee
Manisha Moorjani
Neil J. Ashweek
Original Assignee
Neurocrine Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences, Inc. filed Critical Neurocrine Biosciences, Inc.
Publication of PL3250563T3 publication Critical patent/PL3250563T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL16703250T 2015-01-30 2016-01-29 Podstawione triazole i dotyczące ich sposoby PL3250563T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562110415P 2015-01-30 2015-01-30
US201562259314P 2015-11-24 2015-11-24
EP16703250.7A EP3250563B1 (en) 2015-01-30 2016-01-29 Substituted triazoles and methods relating thereto
PCT/US2016/015740 WO2016123533A1 (en) 2015-01-30 2016-01-29 Substituted triazoles and methods relating thereto

Publications (1)

Publication Number Publication Date
PL3250563T3 true PL3250563T3 (pl) 2022-05-02

Family

ID=55305123

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16703250T PL3250563T3 (pl) 2015-01-30 2016-01-29 Podstawione triazole i dotyczące ich sposoby

Country Status (22)

Country Link
US (4) US9718789B2 (enExample)
EP (1) EP3250563B1 (enExample)
JP (1) JP6728198B2 (enExample)
KR (1) KR102575601B1 (enExample)
CN (1) CN107406420B (enExample)
AU (1) AU2016211292B2 (enExample)
BR (1) BR112017016488A2 (enExample)
CA (1) CA2975474C (enExample)
CY (1) CY1125082T1 (enExample)
DK (1) DK3250563T3 (enExample)
ES (1) ES2905878T3 (enExample)
HR (1) HRP20220327T1 (enExample)
HU (1) HUE058156T2 (enExample)
IL (1) IL253705B (enExample)
LT (1) LT3250563T (enExample)
MX (1) MX378932B (enExample)
PL (1) PL3250563T3 (enExample)
PT (1) PT3250563T (enExample)
RS (1) RS62862B1 (enExample)
RU (1) RU2718049C2 (enExample)
SI (1) SI3250563T1 (enExample)
WO (1) WO2016123533A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2016000542A1 (en) 2014-06-03 2018-04-04 Idorsia Pharmaceuticals Ltd Pyrazole compounds and their use as t-type calcium channel blockers
ES2693052T3 (es) 2014-09-15 2018-12-07 Idorsia Pharmaceuticals Ltd Compuestos de triazol como bloqueantes de los canales de calcio de tipo T
PT3250563T (pt) 2015-01-30 2022-02-09 Neurocrine Biosciences Inc Triazois substituídos e métodos relacionados aos mesmos
HRP20220463T1 (hr) 2016-12-16 2022-05-27 Idorsia Pharmaceuticals Ltd Farmaceutska kombinacija koja sadrži blokator kalcijevih kanala t-tipa
WO2018141961A1 (en) 2017-02-06 2018-08-09 Idorsia Pharmaceuticals Ltd A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
KR102298546B1 (ko) * 2018-10-18 2021-09-08 에이치케이이노엔 주식회사 신규한 n-(이소프로필-트리아졸릴)피리디닐)-헤테로아릴-카르복사미드 유도체 및 이의 용도
CN110669017B (zh) * 2019-10-11 2023-08-04 成都麻沸散医药科技有限公司 多取代三唑甲酸酯类衍生物及其用途
US12570612B2 (en) 2019-10-11 2026-03-10 Chengdu Mfs Pharma. Co., Ltd. Substituted nitrogen heterocyclic compound and anesthetic effect thereof
CN115974799B (zh) * 2021-10-14 2024-08-13 成都百裕制药股份有限公司 氨基甲酸酯取代的醇衍生物及其在医药上的应用
CN121378238B (zh) * 2025-12-23 2026-03-31 蚌埠医科大学 一种芳基烷基唑类衍生物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL50699A0 (en) * 1975-10-28 1976-12-31 Ici America Inc Triazole derivatives
TW513301B (en) * 1999-03-01 2002-12-11 Novartis Ag Pharmaceutical composition for treatment of neuropathic pain and affective and attention disorders
HRP20050053A2 (en) * 2002-09-19 2005-04-30 Solvay Pharmaceuticals B.V. 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
EP1829867A1 (en) * 2006-03-03 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Imidazole compounds having pharmaceutical activity towards the sigma receptor
EP1921073A1 (en) * 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,4-Triazole derivatives as sigma receptor inhibitors
EP1921071A1 (en) * 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,3- triazole derivatives as sigma receptor inhibitors
GB0722077D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
US8742097B2 (en) 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
EP2752411A1 (en) * 2013-01-07 2014-07-09 Laboratorios Del Dr. Esteve, S.A. 1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders
PT3250563T (pt) 2015-01-30 2022-02-09 Neurocrine Biosciences Inc Triazois substituídos e métodos relacionados aos mesmos

Also Published As

Publication number Publication date
RS62862B1 (sr) 2022-02-28
JP6728198B2 (ja) 2020-07-22
US10138214B2 (en) 2018-11-27
US20190169137A1 (en) 2019-06-06
CN107406420A (zh) 2017-11-28
EP3250563A1 (en) 2017-12-06
KR102575601B1 (ko) 2023-09-05
CY1125082T1 (el) 2023-06-09
CN107406420B (zh) 2020-11-06
AU2016211292A1 (en) 2017-08-24
IL253705B (en) 2020-09-30
IL253705A0 (en) 2017-09-28
WO2016123533A1 (en) 2016-08-04
MX2017009824A (es) 2017-11-02
US11021449B2 (en) 2021-06-01
CA2975474C (en) 2023-06-13
US20200399229A1 (en) 2020-12-24
LT3250563T (lt) 2022-04-11
HUE058156T2 (hu) 2022-07-28
PT3250563T (pt) 2022-02-09
KR20170106470A (ko) 2017-09-20
US20170349558A1 (en) 2017-12-07
ES2905878T3 (es) 2022-04-12
AU2016211292B2 (en) 2020-05-07
EP3250563B1 (en) 2022-01-12
RU2017130474A (ru) 2019-02-28
US20160221968A1 (en) 2016-08-04
BR112017016488A2 (pt) 2018-04-10
US10738017B2 (en) 2020-08-11
US9718789B2 (en) 2017-08-01
SI3250563T1 (sl) 2022-04-29
NZ734260A (en) 2024-01-26
RU2017130474A3 (enExample) 2019-06-11
JP2018503661A (ja) 2018-02-08
RU2718049C2 (ru) 2020-03-30
DK3250563T3 (da) 2022-01-31
MX378932B (es) 2025-03-10
CA2975474A1 (en) 2016-08-04
HRP20220327T1 (hr) 2022-05-13

Similar Documents

Publication Publication Date Title
ZA201804070B (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201802794PA (en) Therapeutic compounds and methods
SI3215147T1 (sl) Nevroatenuacijske spojine norketamina in postopki
GB2538731B (en) Methods
PT3250563T (pt) Triazois substituídos e métodos relacionados aos mesmos
GB201608779D0 (en) Methods and compounds
IL247148A0 (en) Pyrazolone compounds and uses thereof
GB201508927D0 (en) Methods
IL251107A0 (en) Compounds and methods
GB201518762D0 (en) Methods
GB201503776D0 (en) Compound and method
GB201507753D0 (en) New compounds and uses
GB201608776D0 (en) Methods and compounds
GB201504763D0 (en) Compounds and uses
GB201515655D0 (en) Methods
GB201501593D0 (en) New compounds and processes
GB201415250D0 (en) Compound and method
GB201512609D0 (en) Methods
GB201719043D0 (en) Methods and compounds
GB201512216D0 (en) Agents uses and methods
GB201509931D0 (en) Hyperthermia method
GB201521339D0 (en) Methods
GB201510756D0 (en) Methods
GB201509909D0 (en) Methods
GB201509813D0 (en) Methods